Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
A new survey finds that over 80% of healthcare professionals notice sex-related differences in disease progression and treatment …
At the 2025 ASCO Gastrointestinal Cancers Symposium, ALX Oncology presents promising Phase II data showing that evorpacept, a …
Oncolytics Biotech discloses compelling new pelareorep combination data—in anal and pancreatic cancer cohorts—highlighting durable responses and tolerable safety …
Multiple clinical-stage biotechs unveil bold 2025 roadmaps—from Denali’s upcoming BLA for Hunter syndrome to Cabaletta’s expanding autoimmune cell …
Mereo BioPharma’s Phase 3 study in osteogenesis imperfecta progresses to interim analysis, while alvelestat gains momentum toward EU orphan …
Hoyos’s inhaled mRNA-based therapy enters first-in-human testing for asthma—a milestone that could redefine treatment for chronic respiratory disease.
A landmark U.S. FDA nod for Datopotamab deruxtecan (Datroway) marks a promising advance for treating metastatic HR‑positive, HER2‑negative …
Neumora Therapeutics sees its share value collapse as its lead antidepressant candidate, navacaprant, fails to outperform placebo in …
CMS approval of Tempus’s AI-powered ECG‑AF algorithm marks its inclusion under U.S. Medicare reimbursement, enabling broader access to …
Already a subscriber? Log in